Ticker Details
Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.
IPO Date:	May 22, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$217.94M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.96 | 3.81%
Avg Daily Range (30 D):	$0.16 | 2.20%
Avg Daily Range (90 D):	$0.29 | 3.18%

Institutional Daily Volume
Avg Daily Volume:	.41M
Avg Daily Volume (30 D):	.41M
Avg Daily Volume (90 D):	.87M

Trade Size
Avg Trade Size (Sh.):	65
Avg Trade Size (Sh.) (30 D):	66
Avg Trade Size (Sh.) (90 D):	77

Institutional Trades
Total Institutional Trades:	2,093
Avg Institutional Trade:	$2.04M
Avg Institutional Trade (30 D):	$.61M
Avg Institutional Trade (90 D):	$1.23M
Avg Institutional Trade Volume:	.07M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.28M
Avg Closing Trade (30 D):	$.66M
Avg Closing Trade (90 D):	$1.31M
Avg Closing Volume:	79.27K

News

Oct 23, 2025 @ 1:15 PM Cathie Wood Goes Shopping: 3 Stocks She Just Bough... Source: Rick Munarriz

Sep 29, 2025 @ 5:35 PM 10 Health Care Stocks With Whale Alerts In Today's... Source: Benzinga Staff Writer

Aug 5, 2025 @ 10:00 AM Lipid Nanoparticles Market Industry Trends, Key Gr... Source: Researchandmarkets.Com

Jul 18, 2025 @ 8:56 AM RNA Therapeutics and RNA Vaccines Market Industry ... Source: Researchandmarkets.Com

Jun 20, 2025 @ 2:59 PM Flu RNA Vaccines Market Research Report 2025-2034 ... Source: Researchandmarkets.Com

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-2.46	$-.49	$-.34
Diluted EPS	$-2.46	$-.49	$-.34
Revenue	$97.6M	$17.15M	$28.3M
Gross Profit
Net Income / Loss	$-66.71M	$-13.45M	$-9.18M
Operating Income / Loss	$-78.35M	$-16.51M	$-11.62M
Cost of Revenue
Net Cash Flow	$-56.82M	$-16.11M	$-20.48M
PE Ratio

Splits
Nov 16, 2017	1:7